ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
동종 세포 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에 CAGR은 10.8%를 나타낼 것으로 예측되고 18억 1,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 첨단 의료 치료에 대한 수요 증가, 새로운 동종 세포 치료법에 대한 수요 확대, 임상 시험 건수 증가, 환자 인구 증가, 소득 수준 상승 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 기술적 발전, 파트너십, 대기업 간 협력, 인수합병, 신제품 출시 등이 포함됩니다.
향후 5년간 10.8% 성장이라는 전망치는 해당 시장에 대한 이전 추정치 대비 0.6% 소폭 하향 조정된 수치입니다. 이러한 하향 조정은 주로 미국과 타국 간 관세 영향에 기인합니다. 무역 긴장은 일본과 벨기에에서 개발된 기증자 유래 줄기세포 제품 및 이식 공학 시스템의 가격을 상승시켜 미국 이식 의학을 저해할 수 있으며, 이는 암 치료 지연과 세포 치료 센터 비용 증가로 이어질 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 영향이 더욱 광범위하게 나타날 것입니다.
만성 질환의 증가는 동종 세포 치료 시장 확장을 촉진할 것으로 예상됩니다. 장기간 지속되며 지속적인 의료 관리가 필요한 만성 질환은 일상 기능 저하와 삶의 질 감소를 초래할 수 있습니다. 이러한 질환의 유병률은 개질된 생활 습관, 유전적 요인, 환경 독소 및 오염물질 노출에서 기인합니다. 동종 세포 치료는 건강한 기증자 세포를 활용해 기능 장애를 보이는 수혜자 세포나 조직을 보수, 대체 또는 조절함으로써 광범위한 만성 질환 치료에 상당한 가능성을 제시합니다. 예를 들어 미국 국립생물공학정보센터(NCBI)의 보고서에 따르면 2050년까지 50세 이상에서 하나 이상의 만성 질환을 앓고 있는 사람이 99.5% 증가하고 2020년 7,152만명에서 1억 4,266만명으로 증가할 것으로 예측됩니다. 그 결과, 만성 질환 증가가 동종 세포 치료 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 동종 세포 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 동종 세포 세포 치료 시장 : 성장률 분석
세계의 동종 세포 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 동종 세포 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 동종 세포 치료 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 동종 세포 치료 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
줄기세포 치료
비줄기세포 치료
세계의 동종 세포 치료 시장 : 치유 영역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
혈액 질환
피부 질환
기타 치료 영역
세계의 동종 세포 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
연구기관
세계의 동종 세포 치료 시장, 줄기세포 치료 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
조혈모 세포 치료
중간엽 줄기세포 치료
유도만능줄기세포 치료
신경줄기세포 치료
기타 줄기세포 치료
세계의 동종 세포 치료 시장, 비줄기세포 치료 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
T세포 치료
NK 세포 치료
수지상세포 치료
기타 비줄기세포 치료
제7장 지역별 및 국가별 분석
세계의 동종 세포 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 동종 세포 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
동종 세포 치료 시장 : 경쟁 구도
동종 세포 치료 시장 : 기업 프로파일
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Bluebird Bio Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Poseida Therapeutics Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Fate Therapeutics Inc.
Fortress Biotech Inc.
Sorrento Therapeutics Inc.
Eureka Therapeutics Inc.
Juno Therapeutics Inc.
Adaptimmune Therapeutics plc
Cellectis SA
TrakCel Ltd.
Promab Biotechnologies Inc.
Ziopharm Oncology Inc.
Allogene Therapeutics Inc.
Century Therapeutics Inc.
Autolus Therapeutics plc
Bellicum Pharmaceuticals Inc.
Minerva Biotechnologies Corporation
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
동종 세포 치료 시장(2029년) : 새로운 기회를 제공하는 국가
동종 세포 치료 시장(2029년) : 새로운 기회를 제공하는 부문
동종 세포 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Allogeneic cell therapy involves harvesting cells from a donor to treat a recipient. Its purpose is to replace or repair damaged tissues, modulate immune responses, or address conditions such as cancer, genetic disorders, and autoimmune diseases.
There are two main types of allogeneic cell therapy stem cell therapies and non-stem cell therapies. Stem cell therapies use stem cells to repair or replace damaged tissues or organs, aiming to prevent or treat a range of diseases and conditions. These therapies are applied in various medical fields, including hematological disorders, dermatological disorders, and other therapeutic areas, utilized by hospitals, specialty clinics, and research organizations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The allogenic cell therapy market research report is one of a series of new reports from The Business Research Company that provides allogenic cell therapy market statistics, including allogenic cell therapy industry global market size, regional shares, competitors with a allogenic cell therapy market share, detailed allogenic cell therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the allogenic cell therapy industry. This allogenic cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The allogeneic cell therapy market size has grown rapidly in recent years. It will grow from $1.08 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to an increased focus on tailoring donor cell selection and genetic modifications, increased population, increase in the global burden of chronic diseases, increased awareness, and increase in the number of collaborations for biosimilar development.
The allogeneic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to the increasing need for advanced medical treatments, growing demand for novel allogeneic cell therapies, rising number of clinical trials, growing patient population contributions, and rising income levels. Major trends in the forecast period include technology advancements, partnerships, big companies collaborating with others, merger and acquisitions, new product launch.
The forecast of 10.8% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. transplant medicine by inflating prices of donor-derived stem cell products and graft engineering systems developed in Japan and Belgium, resulting in delayed cancer treatments and higher cellular therapy center costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rise in chronic diseases is expected to propel the expansion of the allogeneic cell therapy market. Chronic illnesses, characterized by prolonged duration and necessitating continual medical care, can impede daily functioning and diminish life quality. These conditions' prevalence stems from altered lifestyle habits, genetic inheritance, and exposure to environmental toxins and pollutants. Allogeneic cell therapy offers substantial promise in addressing a broad spectrum of chronic diseases, utilizing healthy donor cells to repair, substitute, or regulate dysfunctional recipient cells or tissues. For example, a report from the National Center for Biotechnology Information (NCBI) projected a 99.5% increase in individuals aged 50 and above suffering from one or more chronic ailments by 2050, rising from 71.52 million in 2020 to 142.66 million. Consequently, the escalating occurrence of chronic diseases propels the allogeneic cell therapy market's growth.
Key players in the allogeneic cell therapy sector are concentrating on pioneering solutions, such as cell processing platforms, to fortify their market standing. These platforms encompass systems and technologies employed in preparing and manipulating cells for therapeutic purposes, including isolation, purification, expansion, modification, and quality assurance to ensure clinical suitability. For instance, in March 2024, Getinge, a Swedish healthcare entity, collaborated with CellRev, a UK biotech firm, to introduce Livit ACE, a continuous cell processing platform for Adherent Cell Expansion (ACE). This cutting-edge platform integrates advanced automation and bioprocessing technologies, markedly augmenting cell production efficiency and scalability. Notable features include top-tier cell isolation and purification systems ensuring high purity and viability, robust expansion capabilities for generating ample therapeutic cells, advanced genetic modification tools for precise cell engineering, and stringent quality control protocols to ensure product safety and efficacy.
In February 2024, AstraZeneca, a UK-based pharmaceutical company specializing in oncology and rare diseases, acquired Gracell Biotechnologies for an undisclosed amount. This strategic acquisition allows AstraZeneca to enhance its portfolio in oncology and rare diseases by integrating Gracell Biotechnologies' advanced cell therapy capabilities. Gracell's expertise in allogeneic cell therapy could accelerate the development of innovative treatments for challenging cancers and other serious conditions. Gracell Biotechnologies, based in China, is recognized for its pioneering work in cell therapy, aiming to revolutionize the treatment landscape for various cancers and rare diseases.
Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG
North America was the largest region in the allogeneic cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the allogeneic cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The allogeneic cell therapy market includes revenues earned by entities through induced pluripotent stem cell therapy, hematopoietic stem cell transplantation, mesenchymal stem cell (MSC) therapy, induced pluripotent stem cell (IPSC) therapy and chimeric antigen receptor T cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Allogeneic Cell Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on allogeneic cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for allogeneic cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The allogeneic cell therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Stem Cell Therapies; Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders; Dermatological Disorders; Other Therapeutic Area
3) By End User: Hospitals; Specialty Clinics; Research Organizations
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Allogeneic Cell Therapy Market Characteristics
3. Allogeneic Cell Therapy Market Trends And Strategies
4. Allogeneic Cell Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Allogeneic Cell Therapy Growth Analysis And Strategic Analysis Framework
5.1. Global Allogeneic Cell Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Allogeneic Cell Therapy Market Growth Rate Analysis
5.4. Global Allogeneic Cell Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Allogeneic Cell Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Allogeneic Cell Therapy Total Addressable Market (TAM)
6. Allogeneic Cell Therapy Market Segmentation
6.1. Global Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stem Cell Therapies
Non-Stem Cell Therapies
6.2. Global Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hematological Disorders
Dermatological Disorders
Other Therapeutic Area
6.3. Global Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Organizations
6.4. Global Allogeneic Cell Therapy Market, Sub-Segmentation Of Stem Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hematopoietic Stem Cell Therapy
Mesenchymal Stem Cell Therapy
Induced Pluripotent Stem Cells
Neural Stem Cell Therapy
Other Stem Cell Therapies
6.5. Global Allogeneic Cell Therapy Market, Sub-Segmentation Of Non-Stem Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
T-cell Therapies
Natural Killer (NK) Cell Therapies
Dendritic Cell Therapies
Other Non-Stem Cell Therapies
7. Allogeneic Cell Therapy Market Regional And Country Analysis
7.1. Global Allogeneic Cell Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Allogeneic Cell Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
